JP2014518216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518216A5 JP2014518216A5 JP2014516067A JP2014516067A JP2014518216A5 JP 2014518216 A5 JP2014518216 A5 JP 2014518216A5 JP 2014516067 A JP2014516067 A JP 2014516067A JP 2014516067 A JP2014516067 A JP 2014516067A JP 2014518216 A5 JP2014518216 A5 JP 2014518216A5
- Authority
- JP
- Japan
- Prior art keywords
- inclusive
- insulin
- concentration
- composition
- hyaluronidase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161520962P | 2011-06-17 | 2011-06-17 | |
| US61/520,962 | 2011-06-17 | ||
| PCT/US2012/042816 WO2012174478A2 (en) | 2011-06-17 | 2012-06-15 | Stable formulations of a hyaluronan-degrading enzyme |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016200761A Division JP6224802B2 (ja) | 2011-06-17 | 2016-10-12 | ヒアルロナン分解酵素の安定な製剤 |
| JP2017111643A Division JP2017197556A (ja) | 2011-06-17 | 2017-06-06 | ヒアルロナン分解酵素の安定な製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014518216A JP2014518216A (ja) | 2014-07-28 |
| JP2014518216A5 true JP2014518216A5 (cg-RX-API-DMAC7.html) | 2015-07-23 |
Family
ID=46513830
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014516067A Pending JP2014518216A (ja) | 2011-06-17 | 2012-06-15 | ヒアルロナン分解酵素の安定な製剤 |
| JP2016200761A Active JP6224802B2 (ja) | 2011-06-17 | 2016-10-12 | ヒアルロナン分解酵素の安定な製剤 |
| JP2017111643A Pending JP2017197556A (ja) | 2011-06-17 | 2017-06-06 | ヒアルロナン分解酵素の安定な製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016200761A Active JP6224802B2 (ja) | 2011-06-17 | 2016-10-12 | ヒアルロナン分解酵素の安定な製剤 |
| JP2017111643A Pending JP2017197556A (ja) | 2011-06-17 | 2017-06-06 | ヒアルロナン分解酵素の安定な製剤 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2720712B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2014518216A (cg-RX-API-DMAC7.html) |
| KR (2) | KR101874401B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105797140B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2012271359B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013032396A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2839511C (cg-RX-API-DMAC7.html) |
| EA (2) | EA033472B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2566549T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL229749A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX340172B (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ717728A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012174478A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| SI3130347T1 (sl) | 2011-12-30 | 2020-02-28 | Halozyme, Inc. | Variante polipeptida PH20, formulacije in uporabe le-teh |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CA2895875A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Exendin-4 derivatives |
| TWI780236B (zh) * | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| SG10201913433SA (en) * | 2013-02-04 | 2020-03-30 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| AR098168A1 (es) * | 2013-10-25 | 2016-05-04 | Sanofi Sa | Formulación estable de insulina glulisina |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| RU2016132342A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных |
| JP6562902B2 (ja) * | 2014-03-28 | 2019-08-21 | テルモ株式会社 | 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| CN104095871A (zh) * | 2014-07-10 | 2014-10-15 | 青岛蔚蓝生物股份有限公司 | 一种含盐酸林可霉素与硫酸大观霉素的兽用注射液 |
| CA2958145C (en) * | 2014-07-16 | 2023-09-26 | New York University | Use of hyaluronidase for treatment of muscle stiffness |
| AR102869A1 (es) * | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| CN105018457A (zh) * | 2015-07-20 | 2015-11-04 | 宁波美成生物科技有限公司 | 虫荧光素酶稳定剂 |
| CN114835793A (zh) * | 2015-11-16 | 2022-08-02 | Ubi蛋白公司 | 用于延长蛋白质半衰期的方法 |
| KR102295786B1 (ko) | 2016-09-06 | 2021-09-01 | 신파 티엔리 파머슈티컬 컴퍼니 리미티드 (항저우) | 스킨케어 및/또는 상처치유 촉진에 있어서 복령 추출물 및 이의 활성 성분의 용도 |
| US10369190B2 (en) | 2016-09-13 | 2019-08-06 | Allergan, Inc. | Non-protein clostridial toxin compositions |
| CN108070532A (zh) * | 2016-11-16 | 2018-05-25 | 福建力多利生物科技有限公司 | 一种生产葡萄糖氧化酶的方法 |
| US11510967B2 (en) | 2017-09-08 | 2022-11-29 | Eli Lilly And Company | Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol |
| CN107918020B (zh) * | 2017-11-15 | 2019-01-01 | 浙江夸克生物科技有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒 |
| CN118853631A (zh) | 2018-07-25 | 2024-10-29 | 阿特根公司 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| EP3937904A1 (en) * | 2019-03-15 | 2022-01-19 | Eli Lilly and Company | Preserved formulations |
| CN110592056A (zh) * | 2019-09-19 | 2019-12-20 | 昆明理工大学 | 噬菌体裂解酶复合粉剂及其制备方法和应用 |
| CN110713983B (zh) * | 2019-11-04 | 2022-06-10 | 深圳市体内生物医药科技有限公司 | 一种表达透明质酸酶的免疫细胞及其应用 |
| CA3137324A1 (en) * | 2020-01-23 | 2021-07-29 | Alteogen, Inc. | Novel hyaluronidase variants with improved stability and pharmaceutical composition containing the same |
| BR112022019726A2 (pt) | 2020-08-07 | 2023-03-07 | Alteogen Inc | Método para produzir hialuronidase recombinante |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| EP4566674A3 (en) | 2020-12-28 | 2025-08-06 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| JP2024501721A (ja) * | 2020-12-30 | 2024-01-15 | 上海宝済薬業股▲ふん▼有限公司 | 組換えヒトヒアルロニダーゼ製剤およびその用途 |
| WO2023075506A1 (ko) * | 2021-10-29 | 2023-05-04 | (주)알테오젠 | 인간 히알루로니다제 ph20과 약물을 포함하는 약학 조성물 |
| CN115820766B (zh) * | 2021-12-28 | 2024-11-12 | 华熙生物科技股份有限公司 | 一种酶法制备软骨素寡聚糖的方法及软骨素寡聚糖组合物 |
| US20250332252A1 (en) | 2022-06-02 | 2025-10-30 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| IL321554A (en) * | 2022-12-23 | 2025-08-01 | Hanmi Pharmaceutical Co Ltd | Formulations comprising immune stimulating il-2 analog conjugates |
| KR102554775B1 (ko) * | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
| CN117243852A (zh) * | 2023-11-01 | 2023-12-19 | 华熙生物科技股份有限公司 | 一种皮肤外用组合物及其用途 |
| CN119074669B (zh) * | 2024-06-21 | 2025-04-18 | 邢珺月 | 一种靶向缓解化疗心脏毒性的纳米酶及其制备方法和应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| EP0162007A1 (de) * | 1984-04-18 | 1985-11-21 | Geriaco AG | Stabiles, lagerungsfähiges Insulinpräparat zur Behandlung von Akne vulgaris |
| EP0250119A3 (en) * | 1986-06-20 | 1990-04-18 | Vasocor | Atherosclerotic anti-idiotype antibody immunoassay and reagents |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US6093563A (en) | 1994-07-08 | 2000-07-25 | Ibex Technologies R And D, Inc. | Chondroitin lyase enzymes |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5747027A (en) | 1995-04-07 | 1998-05-05 | The Regents Of The University Of California | BH55 hyaluronidase |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US6610292B2 (en) * | 1995-11-22 | 2003-08-26 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders |
| DE69826705T2 (de) | 1997-11-12 | 2006-02-23 | Alza Corp., Palo Alto | Verfahren zur dermalen verabreichung von polypeptiden |
| US6669663B1 (en) * | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
| US6563022B2 (en) * | 1999-07-05 | 2003-05-13 | Toyo Boseki Kabushiki Kaisha | Cotton plants with improved cotton fiber characteristics and method for producing cotton fibers from these cotton plants |
| DK1259562T3 (da) | 1999-12-22 | 2006-04-18 | Nektar Therapeutics Al Corp | Sterisk hindrede derivater af vandoplöselige polymerer |
| MXPA02011481A (es) * | 2000-05-19 | 2003-06-06 | Alcon Inc | Derivados de disulfuro que son utiles para el tratamiento de enfermedades alergicas. |
| US6902548B1 (en) * | 2001-03-19 | 2005-06-07 | Ed Schuler | Use of Streptomyces hyalurolyticus enzyme in ophthalmic treatments |
| US20030125234A1 (en) * | 2001-12-11 | 2003-07-03 | Middaugh Charles Russell | Alteration of protein stability |
| EP2572733A1 (en) | 2003-02-26 | 2013-03-27 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| EP1603541B2 (en) | 2003-03-05 | 2013-01-23 | Halozyme, Inc. | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| WO2004094630A1 (en) * | 2003-04-23 | 2004-11-04 | Hexima Ltd | Insect chymotrypsin and inhibitors thereof |
| US7279457B2 (en) | 2004-03-12 | 2007-10-09 | Biodel, Inc. | Rapid acting drug delivery compositions |
| AU2005227757C1 (en) * | 2004-03-31 | 2009-08-13 | Hexima Ltd | Arabinogalactan protein compositions and methods for fostering somatic embryogenic competence |
| WO2005118799A1 (en) * | 2004-04-15 | 2005-12-15 | Ista Pharmaceuticals, Inc. | Ovine hyaluronidase |
| WO2007047242A2 (en) * | 2005-10-14 | 2007-04-26 | Soll David B | Ophthalmic surgical irrigating solutions containing hyaluronidase |
| US20100210506A1 (en) * | 2005-10-20 | 2010-08-19 | Mdrna, Inc. | Intranasal administration of rapid acting insulin |
| US20090325860A1 (en) * | 2006-08-04 | 2009-12-31 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
| IL186598A0 (en) * | 2007-10-11 | 2008-11-03 | Mohammad Abdulrazik | Composition and method for the treatment or prevention of glaucoma and ocular hypertension |
| EP3760715B1 (en) | 2008-03-06 | 2021-08-04 | Halozyme, Inc. | Large-scale production of soluble hyaluronidase |
| TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| EA022752B1 (ru) | 2008-12-09 | 2016-02-29 | Галозим, Инк. | Длинные растворимые полипептиды рн20 и их использование |
| TWI520745B (zh) * | 2009-07-06 | 2016-02-11 | 賽諾菲阿凡提斯德意志有限公司 | 含甲硫胺酸之胰島素製劑 |
| CN102655853B (zh) | 2009-09-17 | 2015-07-29 | 巴克斯特卫生保健有限公司 | 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法 |
| EP2720713A2 (en) * | 2011-06-17 | 2014-04-23 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme |
| SI3130347T1 (sl) * | 2011-12-30 | 2020-02-28 | Halozyme, Inc. | Variante polipeptida PH20, formulacije in uporabe le-teh |
-
2012
- 2012-06-15 CN CN201610243096.3A patent/CN105797140B/zh active Active
- 2012-06-15 CN CN201280039713.8A patent/CN103974715A/zh active Pending
- 2012-06-15 JP JP2014516067A patent/JP2014518216A/ja active Pending
- 2012-06-15 EP EP12735366.2A patent/EP2720712B1/en active Active
- 2012-06-15 EA EA201501068A patent/EA033472B1/ru not_active IP Right Cessation
- 2012-06-15 MX MX2013014923A patent/MX340172B/es active IP Right Grant
- 2012-06-15 NZ NZ717728A patent/NZ717728A/en unknown
- 2012-06-15 KR KR1020177027130A patent/KR101874401B1/ko active Active
- 2012-06-15 EA EA201400031A patent/EA201400031A1/ru unknown
- 2012-06-15 KR KR1020147001375A patent/KR20140043438A/ko not_active Ceased
- 2012-06-15 CA CA2839511A patent/CA2839511C/en active Active
- 2012-06-15 ES ES12735366.2T patent/ES2566549T3/es active Active
- 2012-06-15 AU AU2012271359A patent/AU2012271359B2/en not_active Ceased
- 2012-06-15 WO PCT/US2012/042816 patent/WO2012174478A2/en not_active Ceased
- 2012-06-15 BR BR112013032396A patent/BR112013032396A2/pt not_active IP Right Cessation
- 2012-06-15 NZ NZ618331A patent/NZ618331A/en not_active IP Right Cessation
-
2013
- 2013-12-02 IL IL229749A patent/IL229749A0/en unknown
-
2016
- 2016-04-19 AU AU2016202472A patent/AU2016202472B2/en active Active
- 2016-10-12 JP JP2016200761A patent/JP6224802B2/ja active Active
-
2017
- 2017-06-06 JP JP2017111643A patent/JP2017197556A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518216A5 (cg-RX-API-DMAC7.html) | ||
| US20240238382A1 (en) | URI Agonist/Vasodilator | |
| US11020459B2 (en) | Factor VIII formulations | |
| KR101978527B1 (ko) | 펩티드 약물의 비경구 주입을 위한 안정한 제형 | |
| AU2007322334B2 (en) | Method of drug delivery for bone anabolic protein | |
| JP6111475B2 (ja) | ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物 | |
| JP2018138578A5 (cg-RX-API-DMAC7.html) | ||
| CN1120019C (zh) | 含NaCl的胰岛素制品 | |
| US20180036411A1 (en) | Stable Formulation of Insulin Glulisine | |
| EP1706150B1 (en) | Stable growth hormone liquid formulation | |
| KR20160105979A (ko) | 인슐린-아연 복합체의 제조 방법 | |
| US20210283259A1 (en) | Protein formulations | |
| KR20200037235A (ko) | 재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료 | |
| CA3011902C (en) | Liquid insulin formulations and methods relating thereto | |
| KR101932247B1 (ko) | 데옥시콜린산 또는 그의 염을 포함하는 조성물 및 효소의 안정화 방법 | |
| IL277721B2 (en) | Medical infusion pump system for the delivery of an insulin compound |